Cancer cell whole-cell cytotoxic response

Cancer cell whole-cell cytotoxic response is a phenotypic screening endpoint rather than a specific molecular target like a receptor or enzyme. It represents the integrated biological outcome of a drug's effect on a cancer cell, typically measured as the inhibition of cell growth or the induction of cell death across various cell lines (ChEMBL, 2024). This approach is foundational in oncology drug discovery, particularly through programs like the NCI-60 Human Tumor Cell Line Screen, which identifies compounds with potent antineoplastic activity regardless of their initial known mechanism (National Cancer Institute, 2023). Because this 'target' captures the sum of all cellular interactions, it is highly effective for identifying cytotoxic agents such as traditional chemotherapeutics that disrupt DNA replication or microtubule dynamics. However, the lack of a specific molecular target at the outset requires subsequent target deconvolution to understand the precise biochemical pathways involved (Moffat et al., 2017). While drugs interacting with this phenotypic response are effective at killing malignant cells, they often present significant safety challenges due to their potential to affect healthy, rapidly dividing tissues, leading to a narrow therapeutic window (NIH, 2023).

Other names

Phenotypic cytotoxicityCell-based growth inhibitionWhole-cell assay responseAntiproliferative activityCancer cell viabilityNCI-60 screening response

The mechanism of action is not singular; it encompasses various pathways including DNA damage, inhibition of mitosis, antimetabolite activity, and induction of programmed cell death, depending on the specific agent being tested in the phenotypic assay (Moffat et al., 2017).